A
Alan M. Sugar
Researcher at Boston University
Publications - 31
Citations - 3705
Alan M. Sugar is an academic researcher from Boston University. The author has contributed to research in topics: Fluconazole & Amphotericin B. The author has an hindex of 17, co-authored 31 publications receiving 3641 citations. Previous affiliations of Alan M. Sugar include Santa Clara Valley Medical Center & University Medical Center.
Papers
More filters
Journal ArticleDOI
A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia
John H. Rex,John E. Bennett,Alan M. Sugar,Peter G. Pappas,Charles van der Horst,John E. Edwards,Ronald G. Washburn,W. Michael Scheld,Adolf W. Karchmer,Alan P. Dine,Marcia Levenstein,C. Douglas Webb +11 more
TL;DR: A multicenter randomized trial that compared amphotericin B with fluconazole as treatment for candidemia, with the most common diagnoses being renal failure, nonhematologic cancer, and gastrointestinal disease.
Journal ArticleDOI
Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal Meningitis
Michael S. Saag,William G. Powderly,Gretchen A. Cloud,P Robinson,Michael H. Grieco,P K Sharkey,Sumner E. Thompson,Alan M. Sugar,Carmelita U. Tuazon,J F Fisher +9 more
TL;DR: Fluconazole is an effective alternative to amphotericin B as primary treatment of cryptococcal meningitis in patients with AIDS and single-drug therapy with either drug is most effective in patients who are at low risk for treatment failure.
Journal ArticleDOI
Prospective Multicenter Surveillance Study of Funguria in Hospitalized Patients
Carol A. Kauffman,Jose A. Vazquez,Jack D. Sobel,Harry A. Gallis,David S. McKinsey,Adolf W. Karchmer,Alan M. Sugar,Patricia Kay Sharkey,Gilbert J. Wise,Richard Mangi,Ann Mosher,Jeannette Y. Lee,William E. Dismukes +12 more
TL;DR: Although fungal urinary tract infections are an increasing nosocomial problem, the significance of funguria is still not clear, and this multicenter prospective surveillance study of 861 patients was undertaken to define the epidemiology, management, and outcomes of fungusuria.
Journal ArticleDOI
NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis
David W. Denning,David W. Denning,Jeanette Y. Lee,Jeanette Y. Lee,John S. Hostetler,John S. Hostetler,Peter G. Pappas,Peter G. Pappas,Carol A. Kauffman,Carol A. Kauffman,Daniel H. Dewsnup,Daniel H. Dewsnup,John N. Galgiani,John N. Galgiani,John R. Graybill,John R. Graybill,Alan M. Sugar,Alan M. Sugar,Antonino Catanzaro,Antonino Catanzaro,Harry A. Gallis,Harry A. Gallis,John R. Perfect,John R. Perfect,Bonita Dockery,Bonita Dockery,William E. Dismukes,William E. Dismukes,David A. Stevens,David A. Stevens +29 more
TL;DR: Oral itraconazole is a useful alternative therapy for invasive aspergillosis with response rates apparently comparable to amphotericin B, and relapse rates among those who completed therapy and those who discontinued early for possible toxicity were 12% and 40%, respectively.
Journal ArticleDOI
Intravascular Catheter Exchange and Duration of Candidemia
John H. Rex,John E. Bennett,Alan M. Sugar,Peter G. Pappas,Jonathan S. Serody,John E. Edwards,Ronald G. Washburn +6 more
TL;DR: Removal and replacement of all intravascular catheters without exchange over a guidewire from a preexisting line on or before the first day the study drug was administered were associated with a reduction in the subsequent mean duration of candidemia.